| DB ID | MyCo_1588 |
| Title | Role of galactomannan determinations in bronchoalveolar lavage fluid samples from critically ill patients with chronic obstructive pulmonary disease for the diagnosis of invasive pulmonary aspergillosis: a prospective study |
| Year | 2012 |
| PMID | 22835335 |
| Fungal Diseases involved | Invasive pulmonary aspergillosis |
| Associated Medical Condition | Critically ill chronic obstructive pulmonary disease (COPD) |
| Genus | Aspergillus |
| Species | versicolor |
| Organism | Aspergillus versicolor |
| Ethical Statement | Beijing Chao-yang Hostipital IRB approved this study and informed consent was requested from patients or their next of kin before they were included in the study. |
| Site of Infection | None |
| Opportunistic invasive | Opportunistic |
| Sample type | Body fluid |
| Sample source | Bronchoalveolar lavage fluid (BALF) |
| Host Group | Human |
| Host Common name | Human |
| Host Scientific name | Homo sapiens |
| Biomarker Name | GM |
| Biomarker Full Name | Galactomannan |
| Biomarker Type | Diagnostic |
| Biomolecule | Protein |
| Geographical Location | China |
| Cohort | In our study, all of the patients were admitted to a respiratory intensive care unit (RICU) because of respiratory failure from February 2009 to December 2009. These patients were older than 18 years and had been diagnosed with severe COPD, stage III or IV according to the Global Initiative for Chronic Obstructive Lung Disease (GOLD). Patients were excluded for: (i) concurrent solid organ tumor; (ii) concurrent hematological system diseases; (iii) organ transplantation; (iv) long-term use of glucocorticoids for reasons other than COPD; and (v) receiving radiation therapy or immunosuppressive drugs. Of 50 critically ill COPD patients admitted, BALF and serum samples were collected in 34 patients. |
| Cohort No. | 34 |
| Age Group | > 18 |
| P Value | p=0.009 |
| Sensitivity | 0.889 |
| Specificity | 1 |
| Positive Predictive Value | 1 |
| MIC | None |
| Fold Change | None |
| Pathway | None |
| Disease Introduction Mechanism | Invasive pulmonary aspergillosis (IPA) is an important cause of mortality in imunocompromised populations, such as hematological and solid-organ transplant patients. In recent years, chronic obstructive pulmonary disease (COPD) patients, especially those who are critically ill and are admitted to an ICU, are being increasingly recognized as belonging to a population at particular risk of IPA. Timely diagnosis of IPA in this population is challenging due to a lack of specific signs and symptoms, which contributes to a high mortality of 67% to 100%. |
| Technique | ELISA |
| Analysis Method | ELISA Based |
| ELISA kits | Sandwich ELISA Kit, Platelia Aspergillus; Sanofi Diagnostics Pasteur, Marnes-La-Coquette, France |
| Assay Data | None |
| Validation Techniques used | ELISA |
| Up Regulation Down Regulation | None |
| Sequence Data | None |
| External Link | None |
